This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A peptide ~~which:~~ comprising the sequence

~~i) comprises the sequence~~

Trp_1-Glu_1-Val-Leu-Cys_1-Trp_2-Thr_1-Trp_3-Glu_2-Thr_2-Cys_2-Glu_3-Arg (SEQ ID NO: 4),

~~ii) competes with SEQ ID NO: 4 for binding FVII/FVIIa in an *in vitro* assay and having~~ wherein between [[1]]zero and [[8]] eight amino acids of SEQ ID NO: 4 are substituted according to the following:

Trp_1 is ~~an amino acid selected from the group consisting of~~ Trp, Phe, Tyr, Leu, Ile, Met, Val ~~and~~or Ala;

Glu_1 is any amino acid;

Val is ~~an amino acid selected from the group consisting of~~ Val, Trp, Phe, Tyr, Leu, Ile, Met ~~and~~or Ala;

Leu is ~~an amino acid selected from the group consisting of~~ Leu, Trp, Phe, Tyr, Ile, Met, Val ~~and~~or Ala;

Trp_2 is ~~amino acid selected from the group consisting of~~ Trp, Phe, Tyr, Leu, Ile, Met, Val ~~and~~ or Ala;

Thr_1 is any amino acid;

Trp_3 is ~~an amino acid selected from the group consisting of~~ Trp, Phe, Tyr, Leu, Ile, Met, Val ~~and~~or Ala;

Glu_2 is any amino acid;

Thr_2 is any amino acid;

Glu_3 is any amino acid;

Arg is ~~an amino acid selected from the group consisting of~~ Arg, Lys, Leu, Trp, His, Met ~~and~~or Ile;

and

~~iii) comprises the peptide of ii)~~ binds FVII/FVIIa in an *in vitro* assay.

2. (currently amended) The peptide of claim 1, ~~which:~~

~~i) comprises the sequence~~

~~Trp_1-Glu_1-Val-Leu-Cys_1-Trp_2-Thr_1-Trp_3-Glu_2-Thr_2-Cys_2-Glu_3-Arg (SEQ ID NO: 4)~~

~~ii) competes with SEQ ID NO: 4 for binding FVII/FVIIa in an *in vitro* assay and having~~ wherein between [[1]]zero and [[8]] eight amino acids of SEQ ID NO: 4 are substituted according to the following:

Trp_1 is ~~an amino acid selected from the group consisting of~~ Trp, Phe ~~and~~or Leu;

Glu_1 is any amino acid;

Val is ~~an amino acid selected from the group consisting of~~ Val ~~and~~or Ile;

Leu is ~~an amino acid selected from the group consisting of~~ Leu, Ile, Met, Val ~~and~~or Ala;

Trp_2 is ~~amino acid selected from the group consisting of~~ Trp, Phe, Tyr, Leu ~~and~~or Met;

Thr_1 is any amino acid;

Trp_3 is ~~an amino acid selected from the group consisting of~~ Trp, ~~Phe and~~or ~~Tyr~~;

Glu_2 is any amino acid;

Thr_2 is any amino acid;

Glu_3 is any amino acid;

Arg is ~~an amino acid selected from the group consisting of~~ Arg, Lys, Leu ~~and~~or Trp[[;]]

~~and~~

~~iii) comprises the peptide of ii)~~.

3. (original) The peptide of claim 2 having an IC_{50} for FVII/FVIIa of less than 1 μM.

4. (original) The peptide of claim 3 having an IC_{50} for FVII/FVIIa of less than 100 nM.

5. (original) The peptide of claim 4 having an IC_{50} for FVII/FVIIa of less than 10 nM.

6. (original) The peptide of claim 5 which binds FVII/FVIIa and inhibits FVIIa activity.

7. (original) The peptide of claim 6 which blocks an activity associated with FVIIa selected from the group consisting of activation of FVII, activation of FIX and activation of FX.

8. (original) The peptide of claim 7 which inhibits activation of FX.

9. (original) The peptide of claim 8 having an IC_{50} for inhibiting FX activation of less than 10 μM.

10. (original) The peptide of claim 9 having an IC_{50} for inhibiting FX activation of less than 100 nM.

11. (original) The peptide of claim 10 having an IC_{50} for inhibiting FX activation of less than 5 nM.

12. (currently amended) The peptide of claim 11, having the following formula:
X_i-~~Cys$_4$-X$_j$-Cys$_2$~~-Trp$_1$-Glu$_1$-Val-Leu-Cys$_1$-Trp$_2$-Thr$_1$-Trp$_3$-Glu$_2$-Thr$_2$-Cys$_2$-Glu$_3$-Arg-X_k
wherein X_i is absent or is between 1 and 100 amino acids; ~~X$_j$ is 5 amino acids~~ and X_k is absent or between 1 and 100 amino acids.

13. (original) The peptide of claim 12 wherein X_i and X_k are between 1 and 50 amino acids.

14. (original) The peptide of claim 13 wherein X_i and X_k are between 1 and 10 amino acids.

15. (currently amended) The peptide of claim 14 having the formula

~~Xaa_1-Xaa_2-Xaa_3-Xaa_4-Xaa_5-Xaa_6-Cys-Xaa_8-Xaa_9-Xaa_{10}-Xaa_{11}-Xaa_{12}-Cys-Xaa_{14}-Xaa_{15}-~~ Trp_1-Glu_1-Val-Leu-Cys_1-Trp_2-Thr_1-Trp_3-Glu_2-Thr_2-Cys_2-Glu_3-Arg-Xaa_{16}-Xaa_{17}-Xaa_{18}, wherein between zero and eight amino acids are substituted according to the following:

Xaa_1 is an amino acid;

Xaa_2 is an amino acid;

~~Xaa_3 is an amino acid selected from the group consisting of~~ Trp_1 is Trp, Phe, Leu, Ala, Met ~~and~~or Val;

~~Xaa_4~~ Glu_1 is an amino acid;

~~Xaa_5~~ Val is ~~an amino acid selected from the group consisting of~~ Val, Ile, Ala, Trp ~~and~~or Tyr;

~~Xaa_6~~ Leu is ~~an amino acid selected from the group consisting of~~ Leu, Ile, Met, Val ~~and~~or Ala;

~~Xaa_8~~ Trp_2 is ~~selected from the group consisting of~~ Trp, Phe, Leu, Met, Ala ~~and~~or Val;

~~Xaa_9~~ Thr_1 is an amino acid

~~Xaa_{10}~~ Trp_3 is ~~an amino acid selected from the group consisting of~~ Trp, Phe, Met ~~and~~or Tyr;

~~Xaa_{11}~~ Glu_2 is an amino acid;

~~Xaa_{12}~~ Thr_2 is an amino acid;

~~Xaa_{14}~~ Glu_3 is an amino acid except proline;

~~Xaa_{15}~~ Arg is ~~an amino acid selected from the group consisting of~~ Arg, Lys, Leu, Trp, His ~~and~~or Met;

Xaa_{16} is an amino acid;

Xaa_{17} is an amino acid; and

Xaa_{18} is an amino acid.

16. (currently amended) The peptide of claim 15, wherein

~~Xaa_3~~ Trp_1 is ~~selected from the group consisting of~~ Trp, Phe, Leu ~~and~~or Ala;

~~Xaa_5~~ Val is ~~selected from the group consisting of~~ Val, Ile ~~and~~or Ala; and

~~Xaa_8~~ Trp_2 is ~~selected from the group consisting of~~ Trp, Phe, Leu, Met ~~and~~or Ala.

17. (currently amended) The peptide of claim 16, wherein

~~Xaa_3~~ Trp_1 is ~~selected from the group consisting of~~ Trp, Phe, ~~and~~or Leu;

~~Xaa_5~~ Val is ~~selected from the group consisting of~~ Val ~~and~~or Ile;

~~Xaa_6~~ Leu is ~~selected from the group consisting of~~ Leu, Ile, Met ~~and~~or Val;

~~Xaa_8~~ Trp_2 is ~~selected from the group consisting of~~ Trp, Phe, Leu ~~and~~or Met;

~~Xaa_{10}~~ Trp_3 is ~~selected from the group consisting of~~ Trp ~~and~~ ~~Phe~~; and

~~Xaa_{15}~~ Arg is ~~selected from the group consisting of~~ Arg, Lys, Leu ~~and~~or Trp.

18. (currently amended) The peptide of claim 17, wherein ~~Xaa_8-Xaa_9-Xaa_{10}-Xaa_{11}-Xaa_{12}-~~ Trp_2-Thr_1-Trp_3-Glu_2-Thr_2 is -Trp-Thr-Trp-Glu-Thr- (SEQ ID NO:100).

19. (withdrawn) A method of inhibiting FVIIa activity comprising the step of:

a) contacting FVIIa with a peptide of claim 1 in the presence of tissue factor and under conditions which allow binding of the compound to FVIIa to occur.

20. (withdrawn) A method for selecting a compound which blocks FVII/FVIIa activation of FX comprising the steps of:

(1) contacting FVII/FVIIa with a compound of claim 1 in the presence and absence of a candidate molecule under conditions which allow specific binding of the compound of claim 1 to FVII/FVIIa to occur;

(2) detecting the amount of specific binding of the compound of claim 1 to FVII/FVIIa that occurs in the presence and absence of the candidate compound wherein the amount of binding in the presence of the candidate compound relative to the amount of binding in the absence of the candidate molecule is indicative of the ability of the candidate compound to block FVII/FVIIa activation of FX.

21. (withdrawn) A method of inhibiting the activation of FX comprising contacting FVII/FVIIa with a compound that prevents the interaction of FVII/FVIIa with a compound of claim 1.

22. (withdrawn) The method of inhibiting the activation of FX of claim 21 comprising contacting FVII/FVIIa with a compound that prevents the interaction of FVII/FVIIa with SEQ ID NO: 4.

23. (withdrawn) The method of claim 22, wherein the contacting occurs *in vivo*.

24. (withdrawn) The method of claim 22, wherein the contacting occurs *in vitro*.

25. (withdrawn) A method of treating a TF/FVIIa mediated disease or disorder in a host in need thereof comprising administering to the host a therapeutically effective amount of a compound of claim 1.

26. (withdrawn) A method of treating a TF/FVIIa mediated disease or disorder in a host in need thereof comprising administering to the host a therapeutically effective amount of the peptide of claim 1.

27. (original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

28. (original) A pharmaceutical composition comprising the peptide of claim 27 and a pharmaceutically acceptable carrier.

29. (original) The composition of claim 28, which is suitable for inhalation.

30. (currently amended) The composition of claim 29, which is dry powder.

31. (currently amended) The composition of claim 29, which is a liquid.

32. (new) A disulfide-constrained peptide comprising the formula
Trp_1-Glu_1-Val-Leu-Cys_1-Trp_2-Thr_1-Trp_3-Glu_2-Thr_2-Cys_2-Xaa-Arg,
wherein between zero and five amino acids are substituted according to the following:
Leu is substituted with Met, Ile, or Val;
Thr_1 is substituted with Ala, Ser, Glu, Gly, Asp, or Gln;
Thr_2 is Gly, Asp, Gln, Ala, Ser, Glu, Thr, Val, or Asn; and
Xaa is any amino acid; and
Arg is Leu, Ser or Trp.

33. (new) A disulfide-constrained peptide of claim 32, wherein the peptide comprises:
Trp_1-Glu_1-Val-Leu-Cys_1-Trp_2-Thr_1-Trp_3-Glu_2-Thr_2-Cys_2-Xaa-Arg,
wherein between zero and five amino acids are substituted according to the following:
Leu is substituted with Met, Ile, or Val;
Thr_1 is substituted with Ala, Ser, Glu, Gly, Asp, or Gln;
Thr_2 is Gly, Asp, Gln, Ala, Ser, Glu, Thr, Val, or Asn; and

Xaa is any amino acid.

34. (new)\ A disulfide-constrained peptide of claim 32, wherein the peptide comprises:

SAEWEVLCWTWEGCGSVGLV	(SEQ ID NO:1) TF53;
SEEWEVLCWTWEDCRLEGLE	(SEQ ID NO:2) TF57;
WEVLCWTWEDCER	(SEQ ID NO:3) TF 64
WEVLCWTWETCER	(SEQ ID NO:4) TF 65
WEVVCWTWETCER	(SEQ ID NO:5) TF 66
EWEVLCWTWETCERGE	(SEQ ID NO:17) TF99;
EEWEVLCWTWETCERGEG	(SEQ ID NO:18) TF100; or
EEWEVLCWTWETCER	(SEQ ID NO:23) TF183.